Trevor John Kilpatrick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9095635/publications.pdf

Version: 2024-02-01

176 papers 12,312 citations

51
h-index

27345 106 g-index

184 all docs

184 docs citations

times ranked

184

16762 citing authors

#	Article	IF	CITATIONS
1	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests Multiple Sclerosis and Related Disorders, 2022, 58, 103393.	0.9	3
2	High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1112-1124.	1.4	10
3	072 Impact of telehealth on multiple sclerosis (MS) outpatient clinics during the COVID-19 pandemic. , 2021, , .		O
4	$011 \hat{a} \in$ Worsening longitudinal reaction time trajectories using the MSReactor computerised battery predicts confirmed EDSS progression. , 2021, , .		0
5	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e2020-e2031.	1.5	7
6	Autoimmune Encephalitis in Long-Standing Schizophrenia: A Case Report. Frontiers in Neurology, 2021, 12, 810926.	1.1	2
7	Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia. Multiple Sclerosis and Related Disorders, 2020, 46, 102516.	0.9	8
8	Multiple Sclerosis as a Syndromeâ€"Implications for Future Management. Frontiers in Neurology, 2020, 11, 784.	1,1	3
9	An Experimental Investigation of White Matter Venous Hemodynamics: Basic Physiology and Disruption in Neuroinflammatory Disease. Frontiers in Neurology, 2020, 11, 476.	1.1	O
10	Increased ankle muscle coactivation in the early stages of multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090587.	0.5	8
11	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102212.	0.9	1
12	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	1.1	27
13	Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the) Tj ETQq1 1 0.784314 Trials, 2020, 21, 100.	rgBT /Ov	erlock 10 Tf 50
14	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	1.8	17
15	Case Report: Confirmation by Metagenomic Sequencing of Visceral Leishmaniasis in an Immunosuppressed Returned Traveler. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1930-1933.	0.6	9
16	Early imaging predictors of longer term multiple sclerosis risk and severity in acute optic neuritis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731986312.	0.5	2
17	A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults. Journal of Nutrition, 2019, 149, 1385-1392.	1.3	36
18	Higher Non-processed Red Meat Consumption Is Associated With a Reduced Risk of Central Nervous System Demyelination. Frontiers in Neurology, 2019, 10, 125.	1.1	14

#	Article	IF	CITATIONS
19	A Neuroethics Framework for the Australian Brain Initiative. Neuron, 2019, 101, 365-369.	3.8	11
20	Fibre-specific white matter changes in multiple sclerosis patients with optic neuritis. NeuroImage: Clinical, 2018, 17, 60-68.	1.4	56
21	MonoMac syndrome with associated neurological deficits and longitudinally extensive cord lesion. BMJ Case Reports, 2018, 2018, bcr-2017-222872.	0.2	5
22	The TAM receptor TYRO3 is a critical regulator of myelin thickness in the central nervous system. Glia, 2018, 66, 2209-2220.	2.5	18
23	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. Frontiers in Neurology, 2018, 9, 16.	1.1	30
24	Reported Changes in Dietary Behavior Following a First Clinical Diagnosis of Central Nervous System Demyelination. Frontiers in Neurology, 2018, 9, 161.	1.1	21
25	Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study. Molecular Medicine, 2018, 24, 27.	1.9	5
26	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. Frontiers in Neurology, 2018, 9, 418.	1.1	8
27	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Annals of Neurology, 2018, 84, 51-63.	2.8	38
28	The TAM receptor Tyro3 regulates myelination in the central nervous system. Glia, 2017, 65, 581-591.	2.5	33
29	Interleukin-2 receptor- $\hat{l}\pm$ proximal promoter hypomethylation is associated with multiple sclerosis. Genes and Immunity, 2017, 18, 59-66.	2.2	23
30	Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores â‰\$.0. NeuroRehabilitation, 2017, 40, 277-284.	0.5	29
31	A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180–190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice. Journal of Neuropathology and Experimental Neurology, 2017, 76, nlw110.	0.9	5
32	JC virus conversion rates in natalizumab treated patients: the melbourne longitudinal cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.15-e1.	0.9	0
33	Multiple Sclerosis: Basic and Clinical. Advances in Neurobiology, 2017, 15, 211-252.	1.3	7
34	Stressful life events and the risk of initial central nervous system demyelination. Multiple Sclerosis Journal, 2017, 23, 1000-1007.	1.4	14
35	Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nature Reviews Neurology, 2017, 13, 742-754.	4.9	89
36	A Brain-Derived Neurotrophic Factor-Based p75 < sup > NTR < /sup > Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination. ENeuro, 2017, 4, ENEURO.0142-17.2017.	0.9	16

#	Article	IF	Citations
37	Fyn is an intermediate kinase that <scp>BDNF</scp> utilizes to promote oligodendrocyte myelination. Glia, 2016, 64, 255-269.	2.5	46
38	A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis. BMC Psychiatry, 2016, 16, 435.	1.1	32
39	Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. Multiple Sclerosis Journal, 2016, 22, 884-892.	1.4	80
40	Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 461-469.	1.4	59
41	Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status. PLoS Genetics, 2016, 12, e1005853.	1.5	29
42	Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor. Glia, 2015, 63, 1005-1020.	2.5	13
43	A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 2015, 203, 139-141.	0.8	10
44	Parallel Changes in Structural and Functional Measures of Optic Nerve Myelination after Optic Neuritis. PLoS ONE, 2015, 10, e0121084.	1.1	21
45	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Human Molecular Genetics, 2015, 24, 5644-5654.	1.4	53
46	The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. PLoS ONE, 2015, 10, e0127080.	1.1	34
47	Inhibitory saccadic dysfunction is associated with cerebellar injury in multiple sclerosis. Human Brain Mapping, 2014, 35, 2310-2319.	1.9	18
48	Ceruloplasmin geneâ€deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution. Journal of Neuroscience Research, 2014, 92, 732-742.	1.3	3
49	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. Journal of Clinical Neuroscience, 2014, 21, 1835-1846.	0.8	15
50	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience, 2014, 21, 1847-1856.	0.8	22
51	Adult Neural Precursor Cells from the Subventricular Zone Contribute Significantly to Oligodendrocyte Regeneration and Remyelination. Journal of Neuroscience, 2014, 34, 14128-14146.	1.7	215
52	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. Journal of Clinical Neuroscience, 2014, 21, 1857-1865.	0.8	19
53	Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. Journal of Clinical Investigation, 2014, 124, 5042-5056.	3.9	26
54	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213

#	Article	IF	Citations
55	A small peptide mimetic of brainâ€derived neurotrophic factor promotes peripheral myelination. Journal of Neurochemistry, 2013, 125, 386-398.	2.1	21
56	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	3.7	140
57	Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 300-308.	1.2	78
58	Oligodendroglial Expression of TrkB Independently Regulates Myelination and Progenitor Cell Proliferation. Journal of Neuroscience, 2013, 33, 4947-4957.	1.7	122
59	Nanodiamonds with silicon vacancy defects for nontoxic photostable fluorescent labeling of neural precursor cells. Optics Letters, 2013, 38, 4170.	1.7	74
60	Occupational Exposure and Risk of Central Nervous System Demyelination. American Journal of Epidemiology, 2013, 177, 954-961.	1.6	17
61	Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes. Human Molecular Genetics, 2013, 22, 2283-2292.	1.4	20
62	Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. Clinical and Experimental Immunology, 2013, 172, 466-474.	1.1	17
63	The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study. Multiple Sclerosis Journal, 2013, 19, 1717-1725.	1.4	30
64	Amine oxidase activity of \hat{l}^2 -amyloid precursor protein modulates systemic and local catecholamine levels. Molecular Psychiatry, 2013, 18, 245-254.	4.1	14
65	Optic Nerve Diffusion Tensor Imaging after Acute Optic Neuritis Predicts Axonal and Visual Outcomes. PLoS ONE, 2013, 8, e83825.	1.1	40
66	EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE). PLoS ONE, 2013, 8, e55948.	1.1	25
67	Investigation of Sequential Growth Factor Delivery during Cuprizone Challenge in Mice Aimed to Enhance Oligodendrogliogenesis and Myelin Repair. PLoS ONE, 2013, 8, e63415.	1.1	13
68	The stretcher spontaneous neurodegenerative mutation models Charcot-Marie-Tooth disease type 4D. F1000Research, 2013, 2, 46.	0.8	1
69	Targeted Ablation of Oligodendrocytes Induces Axonal Pathology Independent of Overt Demyelination. Journal of Neuroscience, 2012, 32, 8317-8330.	1.7	97
70	Extracellular signalâ€regulated kinase 1/2 signaling promotes oligodendrocyte myelination <i>in vitro</i> . Journal of Neurochemistry, 2012, 122, 1167-1180.	2.1	76
71	Adherence to <scp>MRI</scp> protocol consensus guidelines in multiple sclerosis: An <scp>A</scp> ustralian multiâ€centre study. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 594-598.	0.9	14
72	Diffusion tensor imaging of acute inflammatory lesion evolution in multiple sclerosis. Journal of Clinical Neuroscience, 2012, 19, 1689-1694.	0.8	13

#	Article	IF	CITATIONS
7 3	A genome-wide association study in progressive multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1384-1394.	1.4	57
74	Longitudinal Assessment of Antisaccades in Patients with Multiple Sclerosis. PLoS ONE, 2012, 7, e30475.	1.1	25
7 5	Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism. PLoS ONE, 2012, 7, e47379.	1.1	24
76	Optic Nerve Magnetisation Transfer Ratio after Acute Optic Neuritis Predicts Axonal and Visual Outcomes. PLoS ONE, 2012, 7, e52291.	1.1	16
77	Diffusion tensor imaging of the optic radiations after optic neuritis. Human Brain Mapping, 2012, 33, 2047-2061.	1.9	44
78	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
79	Remyelination Is Altered by Bone Morphogenic Protein Signaling in Demyelinated Lesions. Journal of Neuroscience, 2011, 31, 4504-4510.	1.7	83
80	The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatric Allergy and Immunology, 2011, 22, 327-333.	1.1	78
81	Ndrg1 in development and maintenance of the myelin sheath. Neurobiology of Disease, 2011, 42, 368-380.	2.1	75
82	Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. Multiple Sclerosis Journal, 2011, 17, 344-352.	1.4	40
83	Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility. PLoS ONE, 2011, 6, e16964.	1.1	42
84	Gas6 Increases Myelination by Oligodendrocytes and Its Deficiency Delays Recovery following Cuprizone-Induced Demyelination. PLoS ONE, 2011, 6, e17727.	1.1	58
85	Role of Cytokines as Mediators and Regulators of Microglial Activity in Inflammatory Demyelination of the CNS. NeuroMolecular Medicine, 2010, 12, 99-132.	1.8	76
86	Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade., 2010, 126, 82-93.		51
87	Modulation of bone morphogenic protein signalling alters numbers of astrocytes and oligodendroglia in the subventricular zone during cuprizoneâ€nduced demyelination. Journal of Neurochemistry, 2010, 115, 11-22.	2.1	67
88	Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients. PLoS ONE, 2010, 5, e10003.	1.1	45
89	A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. PLoS ONE, 2010, 5, e13454.	1.1	55
90	The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Human Molecular Genetics, 2010, 19, 2134-2143.	1.4	128

#	Article	IF	CITATIONS
91	Latitudinal variation in incidence and type of first central nervous system demyelinating events. Multiple Sclerosis Journal, 2010, 16, 398-405.	1.4	80
92	Influence of methylprednisolone on magnetic resonance and histological measures during cuprizone-induced demyelination. Neuroscience Letters, 2010, 483, 47-52.	1.0	6
93	Brain-Derived Neurotrophic Factor Promotes Central Nervous System Myelination via a Direct Effect upon Oligodendrocytes. NeuroSignals, 2010, 18, 186-202.	0.5	205
94	BDNF Exerts Contrasting Effects on Peripheral Myelination of NGF-Dependent and BDNF-Dependent DRG Neurons. Journal of Neuroscience, 2009, 29, 4016-4022.	1.7	56
95	Effects of Bone Morphogenic Proteins on Neural Precursor Cells and Regulation during Central Nervous System Injury. NeuroSignals, 2009, 17, 255-264.	0.5	33
96	A role for galanin in human and experimental inflammatory demyelination. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15466-15471.	3.3	44
97	The Role of Neurotrophins in the Regulation of Myelin Development. NeuroSignals, 2009, 17, 265-276.	0.5	42
98	TAM Receptor Signalling and Demyelination. NeuroSignals, 2009, 17, 277-287.	0.5	32
99	Control of visually guided saccades in multiple sclerosis: Disruption to higher-order processes. Neuropsychologia, 2009, 47, 1647-1653.	0.7	26
100	Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. Journal of Neuroimmunology, 2009, 211, 105-109.	1.1	28
101	Oligodendrocyte positioning in cerebral cortex is independent of projection neuron layering. Glia, 2009, 57, 1024-1030.	2.5	17
102	Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nature Genetics, 2009, 41, 824-828.	9.4	501
103	HLAâ€DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens, 2009, 74, 17-21.	1.0	40
104	Antisaccade performance in patients with multiple sclerosis. Cortex, 2009, 45, 900-903.	1.1	42
105	Multiple sclerosis: Cognition and saccadic eye movements. Journal of the Neurological Sciences, 2009, 277, 32-36.	0.3	41
106	Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neurolmage, 2009, 45, 679-686.	2.1	84
107	Associations between Silicone Skin Cast Score, Cumulative Sun Exposure, and Other Factors in the Ausimmune Study: A Multicenter Australian Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2887-2894.	1.1	52
108	Role of the inflammatory process in traumatic brain damage. , 2009, , 185-200.		2

#	Article	IF	Citations
109	SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. Tissue Antigens, 2008, 71, 42-50.	1.0	48
110	Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2008, 86, 3548-3555.	1.3	46
111	Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia, 2008, 56, 686-698.	2.5	79
112	Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes and Immunity, 2008, 9, 624-630.	2.2	116
113	Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes and Immunity, 2008, 9, 1-6.	2.2	54
114	Neurotrophin receptor homologâ€2 regulates nerve growth factor signaling. Journal of Neurochemistry, 2008, 106, 1964-1976.	2.1	13
115	Validation of linear cerebral atrophy markers in multiple sclerosis. Journal of Clinical Neuroscience, 2008, 15, 130-137.	0.8	47
116	CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. Journal of Autoimmunity, 2008, 31, 52-58.	3.0	25
117	Gas6 Deficiency Increases Oligodendrocyte Loss and Microglial Activation in Response to Cuprizone-Induced Demyelination. Journal of Neuroscience, 2008, 28, 5195-5206.	1.7	114
118	Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Multiple Sclerosis Journal, 2007, 13, 827-839.	1.4	68
119	MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neurolmage, 2007, 37, 1138-1147.	2.1	75
120	Multidisciplinary rehabilitation for adults with multiple sclerosis. The Cochrane Library, 2007, , CD006036.	1.5	188
121	Illness perception and health-related quality of life in multiple sclerosis. Acta Neurologica Scandinavica, 2007, 116, 293-299.	1.0	72
122	Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. Immunogenetics, 2007, 59, 177-186.	1.2	13
123	Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. Journal of Neurology, 2007, 254, 581-590.	1.8	285
124	Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Multiple Sclerosis Journal, 2006, 12, 620-628.	1.4	427
125	SOCS3 negatively regulates LIF signaling in neural precursor cells. Molecular and Cellular Neurosciences, 2006, 31, 739-747.	1.0	27
126	Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses. Journal of Clinical Neuroscience, 2006, 13, 636-638.	0.8	12

#	Article	IF	Citations
127	Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor. Neuroscience, 2006, 137, 463-472.	1.1	10
128	Multiple sclerosis: disability profile and quality of life in an Australian community cohort. International Journal of Rehabilitation Research, 2006, 29, 87-96.	0.7	77
129	Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life. Clinical and Experimental Immunology, 2006, 146, 463-470.	1.1	34
130	On the utility of data from the International HapMap Project for Australian association studies. Human Genetics, 2006, 119, 220-222.	1.8	19
131	Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia, 2006, 53, 696-703.	2.5	82
132	Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7859-7864.	3.3	71
133	Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2005, 293, 463.	3.8	137
134	Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Human Genetics, 2004, 114, 573-580.	1.8	40
135	Expression of the low-affinity neurotrophin receptor, p75NTR, is upregulated by oligodendroglial progenitors adjacent to the subventricular zone in response to demyelination. Glia, 2004, 48, 64-75.	2.5	49
136	Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. Journal of Neuroscience Research, 2004, 78, 193-199.	1.3	51
137	Neuroglial responses to CNS injury: prospects for novel therapeutics. Expert Review of Neurotherapeutics, 2004, 4, 869-878.	1.4	3
138	The role of neurotransmission and the Chopper domain in p75 neurotrophin receptor death signaling. Progress in Brain Research, 2004, 146, 41-62.	0.9	32
139	LIF receptor signaling modulates neural stem cell renewal. Molecular and Cellular Neurosciences, 2004, 27, 255-266.	1.0	88
140	Serial MRI in multiple sclerosis: a prospective pilot study of lesion load, whole brain volume and thalamic atrophy. Journal of Clinical Neuroscience, 2004, 11, 153-158.	0.8	12
141	Prospects for stem cell transplantation in multiple sclerosis. Journal of Clinical Neuroscience, 2002, 9, 361-367.	0.8	5
142	Genetic Dissection of the Human Leukocyte Antigen Region by Use of Haplotypes of Tasmanians with Multiple Sclerosis. American Journal of Human Genetics, 2002, 70, 1125-1137.	2.6	93
143	Leukemia Inhibitory Factor Is an Autocrine Survival Factor for Schwann Cells. Journal of Neurochemistry, 2002, 73, 96-104.	2.1	7 5
144	LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nature Medicine, 2002, 8, 613-619.	15.2	241

#	Article	IF	CITATIONS
145	Measurement of intracellular cytokines in MS patients treated with \hat{l}^2 -interferon and association of a \hat{l}^2 -interferon induced exacerbation with increased expression of \hat{l}^3 -interferon by monocytes. Journal of Clinical Neuroscience, 2001, 8, 434-436.	0.8	2
146	Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat. Brain Research, 2001, 911, 163-167.	1.1	27
147	Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. Journal of Neuroscience Research, 2000, 59, 712-721.	1.3	37
148	Rat oligodendroglia express c-met and focal adhesion kinase, protein tyrosine kinases implicated in regulating epithelial cell motility. Neuroscience Letters, 2000, 279, 5-8.	1.0	26
149	Immunosuppressive therapy is valuable in aggressive Multiple Sclerosis. Journal of Clinical Neuroscience, 2000, 7, 561-563.	0.8	2
150	The neurotrophins act synergistically with LIF and members of the TGF- \hat{l}^2 superfamily to promote the survival of spiral ganglia neurons in vitro. Hearing Research, 1999, 138, 73-80.	0.9	71
151	Regulation of neural stem cell differentiation in the forebrain. Immunology and Cell Biology, 1998, 76, 414-418.	1.0	57
152	Synergy between TGF- \hat{l}^2 3 and NT-3 to promote the survival of spiral ganglia neurones in vitro. Neuroscience Letters, 1998, 240, 77-80.	1.0	31
153	EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13248-13253.	3.3	292
154	Expression of the Tyro 4/Mek 4/Cek 4 Gene Specifically Marks a Subset of Embryonic Motor Neurons and Their Muscle Targets. Molecular and Cellular Neurosciences, 1996, 7, 62-74.	1.0	86
155	Cell death in the Schwann cell lineage and its regulation by neuregulin Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9229-9234.	3.3	220
156	Increased proliferation of precursor cells in the adult rat brain after targeted lesioning. Brain Research, 1996, 743, 11-16.	1.1	63
157	Lineage specification of neuronal precursors in the mouse spinal cord Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 10079-10083.	3.3	13
158	REGULATION OF NEURAL PRECURSOR DIFFERENTIATION IN THE EMBRYONIC AND ADULT FOREBRAIN. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 559-562.	0.9	12
159	The Regulation of Neural Precursor Cells within the Mammalian Brain. Molecular and Cellular Neurosciences, 1995, 6, 2-15.	1.0	85
160	Growth factors: potential therapeutic applications in neurology Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1445-1450.	0.9	16
161	The engraftment of transplanted primary neuroepithelial cells within the postnatal mouse brain. Neuroscience Letters, 1994, 181, 129-133.	1.0	13
162	The differentiation and survival of murine neurons in vitro is promoted by soluble factors produced by an astrocytic cell line. Journal of Neuroscience Research, 1993, 35, 147-161.	1.3	23

#	Article	IF	CITATIONS
163	Cloning and growth of multipotential neural precursors: Requirements for proliferation and differentiation. Neuron, 1993, 10, 255-265.	3.8	364
164	Leukemia inhibitory factor promotes the neuronal development of spinal cord precursors from the neural tube. Journal of Neuroscience Research, 1992, 33, 476-484.	1.3	47
165	Acute median nerve compression by haemorrhage from acute myelomonocytic leukaemia. Medical Journal of Australia, 1985, 142, 51-52.	0.8	14
166	Microglia. , 0, , 15-26.		0
167	The role of dendritic cells in neuro-inflammation. , 0, , 27-34.		0
168	Negotiating the brain barriers. , 0, , 35-46.		0
169	CD8+ T cell-mediated autoimmune diseases of the CNS. , 0, , 87-96.		0
170	Acute disseminated encephalomyelitis., 0,, 97-108.		0
171	Primary anglitis of the CNS and its mimics. , 0, , 109-124.		0
172	Chronic HIV infection of the CNS., 0,, 137-160.		0
173	Brain inflammation during bacterial meningitis. , 0, , 161-172.		1
174	Parasitic infections of the brain., 0,, 173-184.		0
175	Role of immunomodulation in management of infections of the CNS. , 0, , 221-244.		0
176	Neuro-inflammation., 0,, 245-260.		1